Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 8-K (Current Report)
Date of Report: November 8, 2025
Event: Presentation of new clinical data from the Phase 2b REZOLVE-AD trial at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting.
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on clinical trial updates and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Clinical Results
The filing details new data regarding the investigational drug rezpegaldesleukin for atopic dermatitis (AD) and its impact on comorbid asthma:
- Study Population: The REZOLVE-AD trial enrolled 393 patients with moderate-to-severe AD. A subset of 99 patients had a history of asthma with available Asthma Control Questionnaire (ACQ-5) data.
- Asthma Outcomes (Week 16):
- All three rezpegaldesleukin doses showed a reduction in mean ACQ-5 scores compared to placebo.
- Two dose arms (24 μg/kg q2w and 24 μg/kg q4w) achieved statistical significance (p<0.05) versus placebo.
- Placebo arm patients reported worsening ACQ-5 scores.
- Subgroup Analysis (Baseline ACQ-5 ≥ 0.5):
- In 53 patients, at least half experienced clinically significant improvement across all treatment arms, compared to 13% in the placebo arm.
- In 25 patients with uncontrolled asthma (baseline ACQ-5 ≥ 1.5), all active doses achieved statistical significance (p<0.05) with placebo-adjusted reductions ranging from 1.0 to 1.4.
- Crossover Data (Week 24):
- 42 placebo patients crossed over to high-dose rezpegaldesleukin (24 μg/kg q2w).
- Response rates observed: EASI-75 (60%), vIGA-AD 0/1 (33%), EASI-90 (37%), and Itch NRS (50% in patients with baseline score ≥ 4).
- Safety: Observed safety data were generally consistent with the previously reported profile.
Guidance, Outlook, and Risks
Management Commentary: The Company presented these results in a late-breaking oral session, highlighting the drug's potential benefit for patients with atopic dermatitis and comorbid asthma.
Outlook: No specific financial guidance or future operational milestones were provided in this filing.
Risks and Contingencies: The filing includes a standard disclaimer that the information is furnished and not "filed" for liability purposes under Section 18 of the Exchange Act. The Company explicitly undertakes no obligation to update, supplement, or amend the attached materials.
Key Facts for Investor Verification
- Verify the full text of the press release (Exhibit 99.1) for complete statistical tables and safety data details.
- Confirm the timeline for potential Phase 3 trial initiation based on these Phase 2b results.
- Review the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor regulatory feedback regarding the asthma indication, as this was a pre-planned analysis within an AD trial.